Serum adiponectin and resistin levels in de novo and relapsed acute lymphoblastic leukemia children patients

Iranian Journal of Public Health

Volumn 42, Issue 5, 2013, Pages 504-510

  El Baz, Hatim A ^a,b   Mosa, Tamer E ^a   Elabd, Elham M ^a   Ramadan, Amal ^a   Elharoun, Ahmed S ^b,c   Elmorsy, Elsayed A ^b,d   Fouda, Manal I ^d  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c MENOUFIA UNIVERSITY   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

Author keywords

Acute lymphoblastic leukemia; Adiponectin; Resistin

Indexed keywords

EID: 84879133219     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Young G, Toretsky JA, Campbell AB, Eskenazi AE (2000). Recognition of common child-hood malignancies. American Family Physician, 61 (7): 2144-2154.
2. Pui CH, Evans WE (2006). Treatment of Acute Lymphoblastic Leukemia. N Engl J Med, 354: 166-178.
3. Hamdy N, Bhatia K, Shaker H, Kamel A, Nazli-Giad-el-Mawla, Abou-Enein M, Yassin D, El-Sharkawy N, Magrath I (1995). Molecular epi-demiology of acute lymphoblastic leukemia in Egypt. Leukemia, 9 (1): 194-202.
4. Esparza SD, Sakamoto KM (2005). Topics in pe-diatric leukemia-acute lymphoblastic leukemia. Med Gen Med, 7 (1): 53.
5. Dalamaga M, Crotty BH, Fargnoli J, Papadavid E, Lekka A, Triantafilli M, Karmaniolas K, Migdalis I, Dionyssiou-Asteriou A, Mantzoros CS (2010). B-cell chronic lymphocytic leukemia risk in association with serum leptin and adi-ponectin: a case-control study in Greece. Can-cer Causes and Control. 2 (9): 1451-1459.
6. Yakar S, Leroith D, Brodt P (2005). The role of the growth hormone/insulin-like growth fac-tor axis in tumor growth and progression: Les-sons from animal models. Cytokine Growth Fac-tor Rev, 16 (4-5): 407-20.
7. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420 (6917): 860-867.
8. Renehan AG, Roberts DL, Dive C (2008). Obes-ity and cancer: pathophysiological and biologi-cal mechanisms. Arch Physiol Biochem, 114 (1): 71-83.
9. Assal HS, Fath-Allah M, Elsherbiny A (2007). Se-rum leptin and adiponectin in obese diabetic and non-diabetic. J Med Sci, 7 (5): 865-869.
10. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005). Prostate cancer and adi-ponectin. Urology, 65 (6): 1168-72.
11. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004). Adiponectin and Breast Cancer Risk. J Clin Endocrinol Metab, 89 (3): 1102-7.
12. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006). Adiponectin in re-lation to childhood myeloblastic leukaemia. Br J Cancer, 94 (1): 156-60.
13. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH (2006). Association between adiponectin, insulin resistance, and endome-trial cancer. Cancer, 106 (11): 2376-81.
14. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007). Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer, 120 (7): 1573-8.
15. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005). Low plasma adiponec-tin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97 (22): 1688-94.
16. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T (2004). Adiponectin, an adipocyte-de-rived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab, 89 (1): 87-90.
17. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y (2005). Adiponectin activates c-Jun NH2-ter-minal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun, 333 (1): 79-87.
18. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y (2004). Adiponectin-induced ant-iangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101 (8): 2476-2481.
19. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, Matsu-moto K, Toyonaga T, Asano T, Nishikawa T, Araki E (2005). Suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res, 97 (8): 837-44.
20. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, Scalia R and Goldstein BJ (2006). Adiponectin sup-pression of high-glucose-induced reactive oxy-gen species in vascular endothelial cells: evi-dence for involvement of a cAMP signaling pathway. Diabetes, 55 (6): 1840-6.
21. Govindarajan B, Klafter R, Miller MS, Mansur C, Mizesko M, Bai X, LaMontagne K Jr, Arbiser JL (2002). Reactive oxygen-induced car-cinogenesis causes hypermethylation of p16 (Ink4a) and activation of MAP kinase. Mol Med, 8 (1): 1-8.
22. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S (2001). Resistin / Fizz3 expression in relation to obesi-ty and peroxisome proliferator-activated recep-tor-gamma action in humans. Diabetes, 50 (10): 2199-202.
23. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA (2003). Resistin is expressed in hu-man macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun, 300 (2): 472-6.
24. Sun CA, Wu MH, Chu CH, Chou YC, Hsu GC, Yang T, Chou WY, Yu CP, Yu JC (2010). Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat, 123 (3): 869-876.
25. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T, Shimada Y (2009). Adipocytokine levels in gas-tric cancer patients: resistin and visfatin as bio-markers of gastric cancer. J Gastroenterol, 44 (7): 685-690.
26. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005). Resistin is an in-flammatory marker of atherosclerosis in hu-mans. Circulation, 111 (7): 932-9.
27. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC (2005). Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism, 54 (4): 471-5.
28. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Damianos A, Chrousos G, Papassotiriou I (2010). Serial plasma concen-trations of adiponectin, leptin, and resistin during therapy in children with acute lym-phoblastic leukemia. J Pediatr Hematol Oncol, 32 (1): 8-13.
29. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96 (5): 1723-1732.
30. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res, 9 (15): 5699.
31. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004). Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab, 89 (3): 1160-3.
32. Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, Avramis VI, Louie SG, Butturini A, Heisterkamp N, Mittelman SD (2009). Adipocytes impair leu-kemia treatment in mice. Cancer Res, 69 (19): 7867-74.
33. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA (2002). Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma con-centration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes, 51 (6): 1884-1888.
34. Arditi JD, Venihaki M, Karalis KP Chrousos GP (2007). Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hor-monal link between obesity and cancer. Horm Metab Res, 39 (1): 9-13.
35. Nishihara T, Baba M, Matsuda M, Inoue M, Nishizawa Y, Fukuhara A, Araki H, Kihara S, Funahashi T, Tamura S, Hayashi N, Iishi H, Shimomura I (2008). Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J Gastroentrol, 14 (42): 6473-6480.
36. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999). Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 257 (1): 79-83.
37. Guzik TJ, Mangalat D, Korbut R (2006). Adipocytokines-novel link between inflam-mation and vascular function? J Physiol Pharmacol, 57 (4): 505-528.
38. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006). Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical charac-teristics. Exp Oncol, 28 (3): 241-244.
39. Housa D, Housová J, Vernerová Z, Haluzík M (2006). Adipocytokines and cancer. Physiol Res, 55 (3): 233-244.
40. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C (2006). Adipokine resistin pro-motes in vitro angiogenesis of human endo-thelial cells. Cardiovasc Res, 70 (1): 146-157.
41. Mohammad-Shahi M, Rafiei H, Karandish M, Omidian K, Haidari F (2012). Effect of calorie restriction supplemented with genistein on se-rum levels of glucose, lipid profile and inflam-matory markers (resistin and hsCRP) in obese rates. Asian J Biochem, 7: 98-105.